vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Origin Bancorp, Inc. (OBK). Click either name above to swap in a different company.
Origin Bancorp, Inc. is the larger business by last-quarter revenue ($104.0M vs $62.1M, roughly 1.7× Cytek Biosciences, Inc.). Origin Bancorp, Inc. runs the higher net margin — 26.6% vs -70.9%, a 97.5% gap on every dollar of revenue. Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 3.9%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
CTKB vs OBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $104.0M |
| Net Profit | $-44.1M | $27.7M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | — |
| Net Margin | -70.9% | 26.6% |
| Revenue YoY | 8.1% | — |
| Net Profit YoY | -557.1% | — |
| EPS (diluted) | — | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $104.0M | ||
| Q4 25 | $62.1M | $103.4M | ||
| Q3 25 | $52.3M | $109.8M | ||
| Q2 25 | $45.6M | $83.5M | ||
| Q1 25 | $41.5M | $94.1M | ||
| Q4 24 | $57.5M | $78.3M | ||
| Q3 24 | $51.5M | $90.8M | ||
| Q2 24 | $46.6M | $96.4M |
| Q1 26 | — | $27.7M | ||
| Q4 25 | $-44.1M | $29.5M | ||
| Q3 25 | $-5.5M | $8.6M | ||
| Q2 25 | $-5.6M | $14.6M | ||
| Q1 25 | $-11.4M | $22.4M | ||
| Q4 24 | $9.6M | $14.3M | ||
| Q3 24 | $941.0K | $18.6M | ||
| Q2 24 | $-10.4M | $21.0M |
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.0% | 36.2% | ||
| Q3 25 | -17.6% | 10.0% | ||
| Q2 25 | -23.3% | 22.3% | ||
| Q1 25 | -36.1% | 30.4% | ||
| Q4 24 | 5.2% | 23.0% | ||
| Q3 24 | -8.2% | 26.1% | ||
| Q2 24 | -18.3% | 27.7% |
| Q1 26 | — | 26.6% | ||
| Q4 25 | -70.9% | 28.5% | ||
| Q3 25 | -10.5% | 7.9% | ||
| Q2 25 | -12.2% | 17.5% | ||
| Q1 25 | -27.5% | 23.8% | ||
| Q4 24 | 16.8% | 18.2% | ||
| Q3 24 | 1.8% | 20.5% | ||
| Q2 24 | -22.4% | 21.8% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | — | $0.95 | ||
| Q3 25 | — | $0.27 | ||
| Q2 25 | — | $0.47 | ||
| Q1 25 | — | $0.71 | ||
| Q4 24 | — | $0.45 | ||
| Q3 24 | — | $0.60 | ||
| Q2 24 | — | $0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $1.3B |
| Total Assets | $461.5M | $10.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $90.9M | $424.2M | ||
| Q3 25 | $93.3M | $626.9M | ||
| Q2 25 | $75.5M | $334.1M | ||
| Q1 25 | $95.3M | $486.2M | ||
| Q4 24 | $98.7M | $470.2M | ||
| Q3 24 | $162.3M | $321.2M | ||
| Q2 24 | $177.9M | $288.1M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $341.7M | $1.2B | ||
| Q3 25 | $378.6M | $1.2B | ||
| Q2 25 | $377.6M | $1.2B | ||
| Q1 25 | $379.6M | $1.2B | ||
| Q4 24 | $395.7M | $1.1B | ||
| Q3 24 | $385.5M | $1.1B | ||
| Q2 24 | $389.1M | $1.1B |
| Q1 26 | — | $10.2B | ||
| Q4 25 | $461.5M | $9.7B | ||
| Q3 25 | $494.9M | $9.8B | ||
| Q2 25 | $493.3M | $9.7B | ||
| Q1 25 | $482.6M | $9.8B | ||
| Q4 24 | $499.5M | $9.7B | ||
| Q3 24 | $491.2M | $10.0B | ||
| Q2 24 | $483.7M | $9.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | — |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -2.9% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-771.0K | $158.9M | ||
| Q3 25 | $-3.9M | $59.3M | ||
| Q2 25 | $108.0K | $20.6M | ||
| Q1 25 | $-125.0K | $35.6M | ||
| Q4 24 | $2.0M | $108.5M | ||
| Q3 24 | $13.2M | $39.6M | ||
| Q2 24 | $6.2M | $11.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-1.8M | $151.1M | ||
| Q3 25 | $-4.6M | $56.8M | ||
| Q2 25 | $-1.5M | $19.6M | ||
| Q1 25 | $-974.0K | $34.8M | ||
| Q4 24 | $1.1M | $86.4M | ||
| Q3 24 | $12.2M | $32.2M | ||
| Q2 24 | $5.2M | $6.5M |
| Q1 26 | — | — | ||
| Q4 25 | -2.9% | 146.0% | ||
| Q3 25 | -8.7% | 51.7% | ||
| Q2 25 | -3.2% | 23.5% | ||
| Q1 25 | -2.3% | 37.0% | ||
| Q4 24 | 1.9% | 110.3% | ||
| Q3 24 | 23.7% | 35.5% | ||
| Q2 24 | 11.0% | 6.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 7.6% | ||
| Q3 25 | 1.3% | 2.3% | ||
| Q2 25 | 3.5% | 1.2% | ||
| Q1 25 | 2.0% | 0.8% | ||
| Q4 24 | 1.6% | 28.1% | ||
| Q3 24 | 2.0% | 8.1% | ||
| Q2 24 | 2.3% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.38× | ||
| Q3 25 | — | 6.88× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | 0.21× | 7.60× | ||
| Q3 24 | 14.05× | 2.13× | ||
| Q2 24 | — | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
